The focus of the Boison laboratory is the brain’s endogenous anticonvulsant and neuroprotectant adenosine. They try to understand how adenosine function and dysfunction contributes to normal and pathological brain function, respectively, and to translate these findings into novel therapeutic approaches. They study adenosine-related physiological and pathophysiological mechanisms in rodent models of disease and in mice with engineered mutations in adenosine metabolism or signaling. Bioengineered polymers, stem cell therapies, and gene therapies are used to afford therapeutic augmentation of the adenosine system. They apply these tools to study disease mechanisms and treatment options in epilepsy, traumatic brain injury, stroke, and schizophrenia.